Metformin Use and Immune Disease Risk in Taiwanese Type 2 Diabetes Patients

A 2000-2018 retrospective cohort study from Taiwan's National Health Insurance Research Database analyzed 40,920 propensity-score-matched patients with type 2 diabetes. It compares metformin users and non-users on outcomes including incident immune-mediated diseases, IMD-related hospitalizations, and all-cause mortality. The dataset supports analysis of dose-response relationships based on cumulative metformin exposure periods.

Use Cases

• Compare the incidence of immune-mediated diseases (IMDs) between matched cohorts of metformin users and non-users.
• Analyze the dose-response relationship between cumulative metformin exposure periods (<182, 182–364, >364 days) and IMD-related hospitalization risk.
• Model the association between metformin use and all-cause mortality hazard ratios using Cox proportional hazards.
• Investigate the correlation between longer cumulative metformin exposure and progressively higher IMD risks versus lower mortality.

Strengths

• Includes a large, matched cohort of 40,920 patients (20,460 users and 20,460 non-users).
• Provides longitudinal data with follow-up from patient diagnosis (2000-2017) until the end of 2018.
• Contains key clinical outcomes: incident IMDs, IMD-related hospitalizations, and all-cause mortality with hazard ratios and confidence intervals.
• Features dose-response analysis segmented by three cumulative metformin exposure periods.

Limitations

• The dataset is small (17.1 KB), likely containing summary results rather than individual patient-level records.
• Limited to the Taiwanese population, which may restrict generalizability to other ethnic or healthcare system contexts.
• As a retrospective observational study, it demonstrates association but cannot establish causality.

Provenance

Source

National Health Insurance Research Database (Taiwan).

Collection Method

Retrospective cohort study using propensity score matching (1:1).

Time Range

2000 to 2018.

Freshness

Data covers patients diagnosed up to 2017 with follow-up until 2018; the record was last updated in 2026.

Geography

Taiwan.